Rezolute, Inc.
Rezolute develops ersodetug, an antibody therapy for refractory hypoglycemia caused by hyperinsulinism.
8-KNov 16Latest SEC filing
Nov 16Latest story
November 2026
October 2026
September 2026
Rezolute develops ersodetug, an antibody therapy for refractory hypoglycemia caused by hyperinsulinism.
November 2026
October 2026
September 2026